{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:11:41Z","timestamp":1789582301031,"version":"build-2803163510"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bpg.2021.101741","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T15:14:38Z","timestamp":1616080478000},"page":"101741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Effect of frequently prescribed drugs on gastric cancer risk"],"prefix":"10.1016","volume":"50-51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2256-4638","authenticated-orcid":false,"given":"Theresa","family":"Weltermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-1744","authenticated-orcid":false,"given":"Lukas","family":"Macke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bpg.2021.101741_bib1","article-title":"Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice","volume":"6","author":"Fuentes","year":"2018","journal-title":"Pharmacy (Basel, Switzerland)"},{"issue":"7","key":"10.1016\/j.bpg.2021.101741_bib2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/00365521.1984.12005824","article-title":"Gastric acid secretion and duodenal ulcer healing during treatment with omeprazole. A Scandinavian Multicentre Study","volume":"19","year":"1984","journal-title":"Scand J Gastroenterol"},{"issue":"21","key":"10.1016\/j.bpg.2021.101741_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215469","article-title":"Problems associated with deprescribing of proton pump inhibitors","volume":"20","author":"Helgadottir","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bpg.2021.101741_bib4","series-title":"Peptic ulcer: chapter closed? Digestive diseases","first-page":"1","author":"Malfertheiner","year":"2020"},{"issue":"2","key":"10.1016\/j.bpg.2021.101741_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000488506","article-title":"Prescription pattern of proton pump inhibitors at hospital admission and discharge","volume":"26","author":"Gamelas","year":"2019","journal-title":"GE Portuguese J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.bpg.2021.101741_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4212\/cjhp.v71i4.2828","article-title":"Inappropriate prescription of proton pump inhibitors in a community setting","volume":"71","author":"Nguyen","year":"2018","journal-title":"Can J Hosp Pharm"},{"issue":"11","key":"10.1016\/j.bpg.2021.101741_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141779","article-title":"Multimorbidities and overprescription of proton pump inhibitors in older patients","volume":"10","author":"Delcher","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.bpg.2021.101741_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejim.2016.10.007","article-title":"The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal","volume":"37","author":"Savarino","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.bpg.2021.101741_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00535-017-1371-9","article-title":"Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth","volume":"53","author":"Su","year":"2018","journal-title":"J\u00a0Gastroenterol"},{"issue":"7","key":"10.1016\/j.bpg.2021.101741_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1060028018760569","article-title":"The risk of community-acquired enteric infection in proton pump inhibitor therapy: systematic review and meta-analysis","volume":"52","author":"Hafiz","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.bpg.2021.101741_bib11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrgastro.2017.117","article-title":"Proton-pump inhibitors: understanding the complications and risks","volume":"14","author":"Malfertheiner","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2021.101741_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000199381","article-title":"Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion","volume":"35","author":"Havu","year":"1986","journal-title":"Digestion"},{"key":"10.1016\/j.bpg.2021.101741_bib13","series-title":"Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication","author":"Leung","year":"2021"},{"issue":"2","key":"10.1016\/j.bpg.2021.101741_bib14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1152\/physrev.00016.2019","article-title":"The physiology of the gastric parietal cell","volume":"100","author":"Engevik","year":"2020","journal-title":"Physiol Rev"},{"issue":"12","key":"10.1016\/j.bpg.2021.101741_bib15","article-title":"Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions","author":"Song","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.bpg.2021.101741_bib16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","article-title":"Proton pump inhibitors alter the composition of the gut microbiota","volume":"65","author":"Jackson","year":"2016","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.bpg.2021.101741_bib17","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.bpg.2021.101741_bib18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/apt.15604","article-title":"Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies","volume":"51","author":"Macke","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2021.101741_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","article-title":"Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology","volume":"42","author":"Lundell","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2021.101741_bib20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12020-016-1099-y","article-title":"Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study","volume":"56","author":"Campana","year":"2017","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.bpg.2021.101741_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.2012.05106.x","article-title":"Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease","volume":"36","author":"Brunner","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bpg.2021.101741_bib22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/apm.12546","article-title":"ECL-cell carcinoids and carcinoma in patients homozygous for an inactivating mutation in the gastric H(+) K(+) ATPase alpha subunit","volume":"124","author":"Fossmark","year":"2016","journal-title":"APMIS : APMIS (Acta Pathol Microbiol Immunol Scand)"},{"issue":"2","key":"10.1016\/j.bpg.2021.101741_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020662","article-title":"Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids-what is the relationship?","volume":"21","author":"McCarthy","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.bpg.2021.101741_bib24","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J Clin"},{"issue":"16","key":"10.1016\/j.bpg.2021.101741_bib25","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3748\/wjg.v19.i16.2560","article-title":"Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies","volume":"19","author":"Ahn","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.bpg.2021.101741_bib26","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.bjc.6605024","article-title":"Proton pump inhibitors and risk of gastric cancer: a population-based cohort study","volume":"100","author":"Poulsen","year":"2009","journal-title":"Br J Canc"},{"issue":"11","key":"10.1016\/j.bpg.2021.101741_bib27","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/gut.2005.086579","article-title":"Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK","volume":"55","author":"Garc\u00eda Rodr\u00edguez","year":"2006","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.bpg.2021.101741_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden","volume":"7","author":"Brusselaers","year":"2017","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.bpg.2021.101741_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199607253350404","article-title":"The risk of stomach cancer in patients with gastric or duodenal ulcer disease","volume":"335","author":"Hansson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.bpg.2021.101741_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/gut.40.2.247","article-title":"Relation between gastric cancer and previous peptic ulcer disease","volume":"40","author":"Molloy","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101741_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-230X-2-17","article-title":"Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials","volume":"2","author":"Salas","year":"2002","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2021.101741_bib32","article-title":"Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease","author":"Sigterman","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"20","key":"10.1016\/j.bpg.2021.101741_bib33","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.3748\/wjg.v21.i20.6341","article-title":"Proton pump inhibitors therapy vs H2 receptor antagonists therapy for upper gastrointestinal bleeding after endoscopy: a meta-analysis","volume":"21","author":"Zhang","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101741_bib34","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.bpg.2021.101741_bib35","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM199604183341603","article-title":"Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication","volume":"334","author":"Kuipers","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.bpg.2021.101741_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000499424","article-title":"Effects of proton pump inhibitor on the distribution of Helicobacter pylori and associated gastritis in patients with gastric atrophy","volume":"101","author":"Gong","year":"2020","journal-title":"Digestion"},{"issue":"10","key":"10.1016\/j.bpg.2021.101741_bib37","first-page":"2120","article-title":"Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole","volume":"91","author":"Graham","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.bpg.2021.101741_bib38","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0016-5085(96)70056-2","article-title":"The effect of environmental pH on the proton motive force of Helicobacter pylori","volume":"111","author":"Meyer-Rosberg","year":"1996","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2021.101741_bib39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2036.1991.tb00047.x","article-title":"Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis","volume":"5","author":"Daw","year":"1991","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bpg.2021.101741_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081913","article-title":"The reduction in gastric atrophy after Helicobacter pylori eradication is reduced by treatment with inhibitors of gastric acid secretion","volume":"20","author":"Niikura","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bpg.2021.101741_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","article-title":"Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study","volume":"67","author":"Cheung","year":"2018","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.bpg.2021.101741_bib42","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1136\/gutjnl-2017-315710","article-title":"Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis","volume":"67","author":"Niikura","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101741_bib43","article-title":"Pharmacological effects and toxicogenetic impacts of omeprazole: genomic instability and cancer","volume":"2020","author":"Paz","year":"2020","journal-title":"Oxid. Med. Cell. Long."},{"issue":"3","key":"10.1016\/j.bpg.2021.101741_bib44","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1053\/j.gastro.2017.10.049","article-title":"Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs","volume":"154","author":"Bjarnason","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2021.101741_bib45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101741_bib46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2004.047100","article-title":"Prostaglandins and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.bpg.2021.101741_bib47","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1152\/physrev.00004.2008","article-title":"Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn\u2019t the stomach digest itself?","volume":"88","author":"Wallace","year":"2008","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.bpg.2021.101741_bib48","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/gast.2000.16510","article-title":"NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2","volume":"119","author":"Wallace","year":"2000","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2021.101741_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.gastro.2004.04.003","article-title":"The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice","volume":"127","author":"Darling","year":"2004","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2021.101741_bib50","article-title":"Prevention of NSAID-induced gastroduodenal ulcers","author":"Rostom","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.bpg.2021.101741_bib51","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/art.21887","article-title":"Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk","volume":"54","author":"Solomon","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.bpg.2021.101741_bib52","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.1780391208","article-title":"Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation","volume":"39","author":"Mahmud","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"3 Pt 1","key":"10.1016\/j.bpg.2021.101741_bib53","first-page":"G421","article-title":"Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity?","volume":"252","author":"Goddard","year":"1987","journal-title":"Am J Physiol"},{"issue":"4","key":"10.1016\/j.bpg.2021.101741_bib54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2559.1993.tb01217.x","article-title":"Gastritis in patients on non-steroidal anti-inflammatory drugs","volume":"23","author":"Quinn","year":"1993","journal-title":"Histopathology"},{"issue":"9","key":"10.1016\/j.bpg.2021.101741_bib55","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02649.x","article-title":"Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin","volume":"22","author":"Yeomans","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2021.101741_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-1-1","article-title":"Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations","volume":"1","author":"de Abajo","year":"2001","journal-title":"BMC Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.bpg.2021.101741_bib57","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/cas.12901","article-title":"Inflammation in gastric cancer: interplay of the COX-2\/prostaglandin E2 and Toll-like receptor\/MyD88 pathways","volume":"107","author":"Echizen","year":"2016","journal-title":"Canc Sci"},{"issue":"9759","key":"10.1016\/j.bpg.2021.101741_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.bpg.2021.101741_bib59","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services task force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.bpg.2021.101741_bib60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jgh3.12226","article-title":"Effect of aspirin use on gastric cancer incidence and survival: a systematic review and meta-analysis","volume":"4","author":"Niikura","year":"2020","journal-title":"JGH open : Open Acc. J. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.bpg.2021.101741_bib61","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/jnci\/djx267","article-title":"Aspirin and risk of gastric cancer after Helicobacter pylori eradication: a territory-wide study","volume":"110","author":"Cheung","year":"2018","journal-title":"J.\u00a0Natl. Canc. Inst."},{"issue":"23","key":"10.1016\/j.bpg.2021.101741_bib62","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/jnci\/djg106","article-title":"Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis","volume":"95","author":"Wang","year":"2003","journal-title":"J.\u00a0Natl. Canc. Inst."},{"issue":"2","key":"10.1016\/j.bpg.2021.101741_bib63","first-page":"798","article-title":"Long-term low-dose aspirin use reduces gastric cancer incidence: a nationwide cohort study. Cancer research and treatment","volume":"48","author":"Kim","year":"2016","journal-title":"Off. J. Korean Canc. Assoc."},{"issue":"9","key":"10.1016\/j.bpg.2021.101741_bib64","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/ijc.33022","article-title":"Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study in the United Kingdom using the Health Improvement Network","volume":"147","author":"Garc\u00eda Rodr\u00edguez","year":"2020","journal-title":"Int J Canc"},{"issue":"7","key":"10.1016\/j.bpg.2021.101741_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071522","article-title":"Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis","volume":"8","author":"Ye","year":"2013","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.bpg.2021.101741_bib66","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12885-020-07117-4","article-title":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Canc"},{"issue":"5","key":"10.1016\/j.bpg.2021.101741_bib67","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2174\/1871520613666131129105035","article-title":"Statins and cancer","volume":"14","author":"Vallianou","year":"2014","journal-title":"Anti Canc Agents Med Chem"},{"issue":"10","key":"10.1016\/j.bpg.2021.101741_bib68","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00228-013-1547-z","article-title":"Statins are associated with reduced risk of gastric cancer: a meta-analysis","volume":"69","author":"Wu","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.bpg.2021.101741_bib69","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/annonc\/mdt150","article-title":"Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis","volume":"24","author":"Singh","year":"2013","journal-title":"Ann Oncol : Off. J. European Soc. Med. Oncol."},{"key":"10.1016\/j.bpg.2021.101741_bib70","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/1471-2407-12-596","article-title":"Statins and the risk of gastric cancer in diabetes patients","volume":"12","author":"Lee","year":"2012","journal-title":"BMC Canc"},{"issue":"4","key":"10.1016\/j.bpg.2021.101741_bib71","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/pds.4688","article-title":"Statin use and survival in patients with gastric cancer in two independent population-based cohorts","volume":"28","author":"Spence","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.bpg.2021.101741_bib72","first-page":"355","article-title":"Long-term statin therapy improves oncological outcome after radical gastrectomy for stage II and III gastric cancer","volume":"34","author":"Nam","year":"2014","journal-title":"Anticancer Res"},{"issue":"18","key":"10.1016\/j.bpg.2021.101741_bib73","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.ejca.2010.07.036","article-title":"The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial","volume":"46","author":"Konings","year":"2010","journal-title":"Eur J Canc"},{"issue":"16","key":"10.1016\/j.bpg.2021.101741_bib74","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.ejca.2014.08.005","article-title":"Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study","volume":"50","author":"Kim","year":"2014","journal-title":"Eur J Canc"},{"issue":"3","key":"10.1016\/j.bpg.2021.101741_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.152820","article-title":"TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer","volume":"216","author":"Hong","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"3","key":"10.1016\/j.bpg.2021.101741_bib76","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.bpg.2021.101741_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000480149","article-title":"Additional benefits of routine drugs on gastrointestinal cancer: statins, metformin, and proton pump inhibitors","volume":"36","author":"Joo","year":"2018","journal-title":"Dig Dis"},{"issue":"Pt A","key":"10.1016\/j.bpg.2021.101741_bib78","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.phrs.2016.10.006","article-title":"Metformin: an anti-diabetic drug to fight cancer","volume":"113","author":"Daugan","year":"2016","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.bpg.2021.101741_bib79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.29.02.06.dc05-1558","article-title":"Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin","volume":"29","author":"Bowker","year":"2006","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.bpg.2021.101741_bib80","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s00125-010-1804-y","article-title":"Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A diabetes outcome progression trial) and RECORD (rosiglitazone evaluated for cardiovascular outcomes and regulation of glycaemia in diabetes) clinical trials","volume":"53","author":"Home","year":"2010","journal-title":"Diabetologia"},{"issue":"33","key":"10.1016\/j.bpg.2021.101741_bib81","doi-asserted-by":"crossref","first-page":"55622","DOI":"10.18632\/oncotarget.16973","article-title":"Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bpg.2021.101741_bib82","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s12094-020-02304-y","article-title":"The effect of metformin on gastric cancer in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"22","author":"Shuai","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101741_bib83","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000446301","article-title":"Different pathophysiology of gastritis between East and west? An asian perspective","volume":"1","author":"Suzuki","year":"2016","journal-title":"Inflam. Intestinal Dis."},{"issue":"8","key":"10.1016\/j.bpg.2021.101741_bib84","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/apt.12660","article-title":"Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study","volume":"39","author":"Kim","year":"2014","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691821000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691821000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:02:51Z","timestamp":1761498171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691821000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":84,"alternative-id":["S1521691821000172"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2021.101741","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of frequently prescribed drugs on gastric cancer risk","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2021.101741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101741"}}